CM BANK

3968
54.7001.39% ( +0.750 )
Delay Closed: Nov 16, 16:08:11

Posts

Share your thoughts

What's on your mind?

0 / 2,000
19.8k followers · 0 opinions
▲Bullish50%
50%Bearish▼
  • D
    Dolphin Research

    H World (Trans): Rev. guidance raised again; margins take back seat near term for investment

    Adj. EBITDA rose 22.8% YoY, with margin up 370bps to 39.8%. Full-year revenue guidance was raised again to 9%–10% growth. From Q4, management will step up strategic investments in brand, membership, and technology, so near-term margins may fluctuate; they also launched an approx. two-year network quality upgrade plan, and full-year store closures will slightly exceed the initial guidance.

    图片 1,共 1 张
    Conference MinutesHTHT
  • T
    Tiffany lover

    The Monetary Authority of Singapore tightened the slope of the Singapore dollar's nominal effective exchange rate policy band on April 14 (the first rate hike in four years) and raised its 2026 inflation forecast to 1.5–2.5%; the government launched a support plan worth nearly S$1 billion.

    This is the first time the Singapore government has responded to the impact of the Middle East conflict on Singapore's economic system.

    C
    Captain's Watch
    ☕️ [Task Coins Giveaway] Daily Market Talk

    🇺🇸🇭🇰🇸🇬 Big moves across US, HK, SG markets. Join the chat & earn Task Coins!

  • H
    Heroic Lifesaver

    Well not surprising isn’t it that MAS did what it did. It was just the responsible thing to do with the impending uptick in inflation.

    C
    Captain's Watch
    ☕️ [Task Coins Giveaway] Daily Market Talk

    🇺🇸🇭🇰🇸🇬 Big moves across US, HK, SG markets. Join the chat & earn Task Coins!

  • B
    Boss's Boss

    $XTALPI(02228.HK) Discussing risks at a stage peak. My personal view is that PharmaTech's fundamentals currently appear sound, and a continued bullish stance based on fundamentals is justified. The biggest risk stems from the source of liquidity. Overall, the liquidity and stock price of PharmaTech are undoubtedly supported by funds from the A-share market. Therefore, from a certain perspective, the sentiment in the A-share market is a crucial support for the stock price at this stage. Of course, we are fortunate to witness the start of a historic slow bull market just as fundamentals have significantly improved. The current pace suggests we are still in the early to mid-stages of the bull market (frankly, I’ve been feeling a bit restless lately, wanting to grow my RMB holdings—seeing my deposits at China Merchants Bank not increasing makes me anxious). However, given the rhythm of the A-share market and the habits of retail investors, confidence in a long-term slow bull market is lacking. How long can this last? Six months? Until Q1 or Q2 next year? Will it? Could the A-share market become overly aggressive, leading to massive bubbles and a rush for the exits? From my current perspective, this is the biggest macro risk PharmaTech faces in the medium term. When market sentiment shifts, investors won’t consider fundamentals—they’ll just want to preserve cash... This is the stampede effect.

    MEDIUM HIGH LCW RISK 人 安全客(www.anquanke.com)